If you are asking whether peptides help you lose weight, the honest answer starts with a correction: "peptides" is not one treatment. It is a category holding dozens of different molecules with wildly different levels of evidence behind them. A few have large, replicated human trials. Most of the ones sold for fat loss have almost none. This guide sorts them by what the research actually supports, so you can tell which is which before anyone offers you a vial.
Key Things to Know
What a Peptide Actually Is
A peptide is a short chain of amino acids that acts as a signaling molecule. That definition describes the chemistry, not an effect. Insulin is a peptide. So is the hormone your gut releases when you eat. The word tells you how the molecule is built, not what it does in your body.
Why "Peptide" Is Not One Treatment
Peptide menus commonly run to two dozen or more distinct molecules, aimed at targets as different as appetite signaling, tissue repair, sleep, cognition, and skin. Grouping them under one label is like asking whether pills work. The molecule is the question, and each one has its own evidence file.
That matters most in weight management, where a peptide with three phase 3 trials and a peptide with a handful of rodent studies are often listed side by side on the same menu, at similar prices.
Prescription, Not Supplement
Weight-management peptides are prescription medications delivered by subcutaneous injection. They are not over-the-counter supplements and they are not sold as a retail product. At Las Vegas Mobile IV Therapy, a licensed medical professional administers the first dose during the visit and provides guidance to continue at home, and a good-faith exam plus provider approval are required before any of that begins.
Any provider willing to skip the exam is skipping the part that decides whether the medication is safe for you.
What the Evidence Shows, Tier by Tier
Sort any peptide you are offered into one of three tiers: large human weight-loss trials, limited or population-specific human data, and no completed human weight-loss trials. Nearly every molecule on a Las Vegas peptide menu falls into one of them, and the tier tells you how much weight to put on the claim.
Tier 1: Large Human Trials, the GLP-1 Receptor Agonists
This is the only tier with replicated phase 3 weight-loss evidence. In the STEP 1 trial, semaglutide 2.4 mg produced about 15 percent mean body-weight reduction, against roughly 2 to 3 percent on placebo, and the effect held to two years (New England Journal of Medicine). In SURMOUNT-1, tirzepatide at the 15 mg dose produced about 20.9 percent mean body-weight reduction at week 72 (New England Journal of Medicine).
The two were compared head to head for the first time in SURMOUNT-5, where tirzepatide was superior to semaglutide on both body weight and waist circumference at 72 weeks (New England Journal of Medicine). Mechanically, both act on appetite signaling in the brain and slow gastric emptying, so you feel full sooner and for longer. Tirzepatide adds activity at the GIP receptor alongside GLP-1.
What "About 15 to 21 Percent" Actually Means
Those are averages across a trial population, measured on top of the diet and activity support every participant received, with some people well above the average and some well below it. They describe what a study found. They are not a result anyone can promise you, and individual results vary.
Weight-Loss Peptides by Evidence Tier
How much human weight-loss research sits behind each of the molecules commonly offered for fat loss.
| Molecule | Evidence tier | What the research actually covers |
|---|---|---|
| Semaglutide | Large human trials Tier 1 |
STEP 1: about 15 percent mean body-weight reduction, sustained to two years |
| Tirzepatide | Large human trials Tier 1 |
SURMOUNT-1: about 20.9 percent at 72 weeks. Superior to semaglutide in SURMOUNT-5 |
| Tesamorelin | Population-specific Tier 2 |
Visceral fat reduction in HIV-associated lipodystrophy, not general weight loss |
| AOD-9604 | Limited human data Tier 2 |
One 12-week randomized trial with a modest result, no large confirmatory program since |
| MOTS-c | No weight-loss trials Tier 3 |
Preclinical metabolic research only. No completed human weight-loss trial |
| CJC-1295 and ipamorelin | No weight-loss trials Tier 3 |
Growth hormone secretagogues studied for hormone response, not for weight outcomes |
| Lipo-C | No weight-loss trials Tier 3 |
A lipotropic injection of MIC and B12. No controlled weight-loss evidence |
Tier 2: Limited or Population-Specific Human Data
Tesamorelin is the peptide most often misfiled. It is a GHRH analog with genuine randomized-trial evidence for reducing visceral adipose tissue, roughly 15 to 20 percent over 26 weeks, but that research was conducted in people with HIV-associated lipodystrophy (meta-analysis of randomized controlled trials, PubMed). Visceral fat in a specific clinical population is not the same endpoint as weight loss in the general population, and the trials were not designed to answer the second question.
AOD-9604, a fragment of the growth hormone molecule, has one randomized placebo-controlled trial in adults with obesity: 12 weeks of daily dosing produced about 2.6 kg of weight loss against 0.8 kg on placebo. No large confirmatory program has followed. One modest trial is a starting point, not a body of evidence.
Tier 3: No Completed Human Weight-Loss Trials
MOTS-c is a mitochondrial-derived peptide studied in preclinical metabolic models. Growth hormone secretagogues such as CJC-1295 and ipamorelin have been studied for their effect on growth hormone release rather than for weight outcomes. Lipo-C is a lipotropic injection of MIC and B12 with no controlled weight-loss evidence behind it. Sermorelin sits in the same category, and if you want the detail on how growth hormone peptides differ, we cover it on the sermorelin service page.
None of that makes these molecules useless for other purposes. It does mean that if someone recommends one to you specifically for weight loss, there is no human trial to point at. Ask for one and see what you are given.
Most of these peptides are compounded or research-use products and are not FDA-approved for the uses described here. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.
Compounded Versus FDA-Approved: The Distinction That Matters Most
This is the fact most peptide pages leave out, and it is the one most likely to affect you. Semaglutide and tirzepatide exist as FDA-approved branded products, sold under names including Ozempic, Wegovy, Mounjaro and Zepbound. A compounded version of the same active ingredient is a different thing. It is prepared by a compounding pharmacy, it is not the FDA-approved product, and it has not been through that approval process.
The regulator has been active here. In September 2025, the FDA issued more than 50 warning letters to companies compounding or manufacturing GLP-1 semaglutide and tirzepatide, citing statements it considered false or misleading. As of early 2025 the agency had logged more than 455 adverse event reports tied to compounded semaglutide and more than 320 tied to compounded tirzepatide, many of them dosing errors by people drawing their own doses from multidose vials. In April 2026 the FDA proposed permanently excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List (U.S. Food and Drug Administration).
Concentration and packaging vary between compounders and sometimes within a single compounder, which is exactly where dosing errors start. That is not an argument against ever using a compounded medication. It is an argument for knowing which one you are being given, who prepared it, and who is supervising your dose. If you are weighing your options locally, our semaglutide program details set out how the medication is prescribed and supervised.
Common Myths About Peptides and Weight Loss
Myth: All Peptides Burn Fat
Only GLP-1 receptor agonists have large human weight-loss trials behind them. The peptides marketed as fat burners mostly sit in tiers 2 and 3, supported by preclinical work or by research in a different clinical population. The category label is doing the persuading, not the data.
Myth: Compounded Semaglutide Is the Same Product
It is not the FDA-approved product, even though the active ingredient shares a name. The FDA's own compounding statement describes concentration and packaging varying between compounders, and links that variation to the dosing errors behind hundreds of adverse event reports.
Myth: Peptides Replace Diet and Exercise
Every published weight-loss figure for these medications comes from a trial where participants also received structured diet and activity support. The medication was studied on top of lifestyle care, not instead of it, and the results reflect both.
When to Talk to a Provider
The useful question is not whether peptides work in general. It is whether a specific molecule is appropriate for you, given your health history, and who will be responsible for your dose. That is a conversation with a prescribing clinician, not a decision to make from a menu.
Who Should Not Take Weight-Management Peptides
GLP-1 receptor agonists carry documented cautions, including a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, pancreatitis, pregnancy or planned pregnancy, and certain gastrointestinal conditions. Your own history may add others. This article is general information, not medical advice, diagnosis, or treatment, and it is not a substitute for talking to your physician. Peptide therapy is elective supportive care and is not emergency care. If you have severe symptoms such as persistent vomiting, severe abdominal pain, chest pain, fainting, or confusion, seek emergency care or call 911.
Questions Worth Asking Any Provider
- Which specific molecule are you recommending, and why that one for me?
- What human evidence exists for that molecule, for weight loss specifically?
- Is this the FDA-approved product or a compounded preparation, and who compounded it?
- Who is the prescribing provider, and who monitors me between doses?
- What happens if it does not work, or if I cannot tolerate the side effects?
Locally, prescriptions are written by Rich Majors, FNP-BC, the ordering provider for the Las Vegas team, and care is delivered under Medical Director Dr. Daniel Olivero, MD. If a weight-management conversation is where you are headed, our medically supervised weight-loss support in Las Vegas is the right starting point, and NAD+ IV therapy in Las Vegas is covered separately for readers who arrived looking at energy and metabolic claims.
Sources and References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine.
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine.
- Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin in HIV-associated lipodystrophy: a meta-analysis of randomized controlled trials. PubMed.
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.
Service Area
Las Vegas Mobile IV Therapy serves the Las Vegas metro and Southern Nevada, 24 hours a day. To reach a provider, call (725) 217-4236.
- Las Vegas
- Henderson
- North Las Vegas
- Summerlin South
- Paradise
- Enterprise
- Sunrise Manor
- Whitney
- Winchester
- Boulder City
- Lake Las Vegas
- Pahrump
- Mesquite
- Laughlin
- Primm
- Searchlight
- Moapa Valley
